N@N

Market Maker Surveillance Report. FLML, GENE, GILT, AZC, MNOV, OOIL, Losing Stocks With Lowest Price Friction For Wednesday, M

May 23, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3832 companies with "abnormal" market making, 2538 companies with positive Friction Factors and 2943 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. FLAMEL TECHNOLOGIES-SP ADR (NASDAQ:FLML), Genetic Technologies Ltd (NASDAQ:GENE), GILAT SATELLITE NETWORKS LTD (NASDAQ:GILT), AUGUSTA RESOURCE CORP (AMEX:AZC), MEDICINOVA INC (NASDAQ:MNOV), ORIGINOIL INC (OTCBB:OOIL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  FLML    $-0.380   -8.68%    68,358       12.44%    481,207      87.56%    -412,849     -10,864 
  GENE    $-0.450   -11.28%   284,846      44.00%    320,979      49.59%    -36,133      -803    
  GILT    $-0.430   -11.44%   32,681       41.38%    46,304       58.62%    -13,623      -317    
  AZC     $-0.140   -8.28%    48,717       16.51%    105,173      35.64%    -56,456      -4,033  
  MNOV    $-1.560   -53.61%   29,572       31.00%    63,134       66.18%    -33,562      -215    
  OOIL    $-0.110   -8.09%    43,005       30.41%    67,968       48.07%    -24,963      -2,269  

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows FLML with a dollar loss Wednesday of $-0.38000 and a Friction Factor of -10,864 shares. That means that it only took 10,864 more shares of selling than buying to move FLML lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

FLAMEL TECHNOLOGIES-SP ADR (NASDAQ:FLML) - Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for life science applications in France. The company develops products based on its nanoparticle Medusa technology, which provides controlled release following injection of therapeutic proteins, peptides, and other large and small molecules; multiparticle Micropump technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement; and Trigger-Lock technology to minimize the misuse and abuse of medications subject to abuse. Its products under development based upon Medusa technology include Interferon-alpha, a naturally occurring protein that the body uses for the treatment of Hepatitis C virus; and FT-105 long-acting basal insulin formulation to meet the basal insulin requirements of diabetic patients. The companys products based on its Micropump technology comprise Trigger Lock, an application that provides a technical solution for the societal problems of intentional and unintentional abuse and misuse of narcotics and other dangerous drugs; and Coreg CR, a formulation of carvedilol phosphate, which is used for the treatment of moderate to severe congestive heart failure, left ventricular dysfunction following myocardial infarction, and hypertension. Flamel Technologies has strategic alliance with Baxter International, Inc.; GlaxoSmithKline; Merck Serono; Pfizer; Corning S.A; and Corning Incorporated. The company was founded in 1990 and is headquartered in Venissieux, France.

Genetic Technologies Ltd (NASDAQ:GENE) - Genetic Technologies Limited operates as a life science company, specializing in the fields of genetics and genomics primarily in Australia. The company provides genetic testing services to human beings for disease susceptibility, parentage, individual identity, forensics, and sports performance; animals, such as dogs, horses, birds, alpacas, exotics, and zoo animals for parentage, pedigree, traits, and disease susceptibility; and plants for traits and disease susceptibility. It also offers canine reproductive services, as well as involves in licensing its non-coding DNA patents. In addition, the company offers BREVAGen, a diagnostic test that informs clinicians and patients about individual, non-familial, sporadic risk of breast cancer for women where a breast biopsy outcome is indeterminate. The company was formerly known as Duketon Goldfields N.L. and changed its name to Genetic Technologies Limited in August 2000. Genetic Technologies Limited was incorporated in 1987 and is based in Fitzroy, Australia.

GILAT SATELLITE NETWORKS LTD (NASDAQ:GILT) - Gilat Satellite Networks Ltd., together with its subsidiaries, provides Internet Protocol (IP) based digital satellite communication and networking products and services worldwide. The company engages in the design, production, and marketing of very small aperture terminals (VSATs) and related VSAT network equipment. Its VSAT products include SkyEdge IP + SkyEdge II IP, a compact IP VSAT; SkyEdge PRO, a multi-service VSAT; SkyEdge ACCESS + SkyEdgeII PRO, a multi-service VSAT; SkyEdge II Extend, an enterprise VSAT; and SkyEdge Armadillo Pro + SkyEdge Armadillo, a VSAT for outdoor applications. The companys VSAT solutions comprise SkyAbis for cellular traffic backhaul that enables operators to expand their market reach; emergency response/rapid deployment that are transportable and man-pack communication solutions; Cisco VSAT NM, a satellite-based networking for Cisco router with Cisco VSAT NM; and Satellite communication on the move for the ground and maritime markets. In addition, it offers StarBand, an VSAT Internet access service; Connexstar Transaction, a low-bandwidth VSAT network; Connexstar Broadband, a broadband VSAT network; Connexstar Performance, a high-bandwidth VSAT network; and Spacenet Custom Networks that are VSAT and hybrid terrestrial WANs. Further, the company provides various solutions, including project management, network design, deployment logistics, implementation and integration, operational services, and maintenance and support. Additionally, it offers NetEdge, a satellite communications solution for corporations and cellular backhaul applications. The company offers its products under the Gilat, Connexstar, SkyAbis, SkyEdge, Spacenet, and StarBand brands. It sells its products primarily to communication service providers and operators that use VSATs to serve enterprise, government, and residential users, as well as directly to end-users. Gilat Satellite Networks Ltd. was founded in 1987 and is headquartered in Petah Tikva, Israel.

AUGUSTA RESOURCE CORP (AMEX:AZC) - Augusta Resource Corporation, through its subsidiaries, engages in the acquisition, exploration, and development of natural mineral resource properties. Its principal project includes Rosemont property, a copper-molybdenum-silver deposit that covers an area of approximately 15,000 acres and is located in Pima County, Arizona. The company was formerly known as Hol-Lac Gold Mines, Limited and changed its name to Augusta Resource Corporation in 1997. Augusta Resource Corporation was founded in 1937 and is headquartered in Vancouver, Canada.

MEDICINOVA INC (NASDAQ:MNOV) - MediciNova, Inc., a biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs principally in the United States. The companys development pipeline includes programs that are in clinical development for the treatment of asthma, acute exacerbations of asthma, multiple sclerosis, central nervous system disorders, interstitial cystitis, solid tumor cancers, generalized anxiety disorder/insomnia, preterm labor, and urinary incontinence. Its principal product development programs consist of MN-221, which completed Phase II clinical trial for the treatment of acute exacerbations of asthma, and completed Phase Ib clinical trial for the treatment of chronic obstructive pulmonary disease; MN-166 that has completed Phase II clinical trial for the treatment of multiple sclerosis; and AV411, which has advanced through multiple Phase I and IIa clinical trials for the treatment of central nervous system disorders. The companys other product development programs include MN-001, which completed Phase II/III clinical trial for the treatment of interstitial cystitis and an oral dosing formulation prototype for the treatment of bronchial asthma; MN-029 that completed Phase I clinical trial for the treatment of solid tumors; MN-305, which completed Phase II/III clinical trial for the treatment of generalized anxiety disorder and Phase II clinical trial for the treatment of insomnia; MN-221 that completed a Phase I clinical trial for the treatment of preterm labor; and MN-246, a Phase I clinical trial completed product for the treatment of urinary incontinence. Its preclinical development products comprise MN-447 and MN-462 for the treatment of thrombotic disorders. The company was founded in 2000 and is headquartered in San Diego, California.

ORIGINOIL INC (OTCBB:OOIL) - OriginOil, Inc., a development stage company, focuses on developing a technology to produce biofuel from algae to replace petroleum in various applications, such as diesel, gasoline, jet fuel, plastics, and solvents. Its patent-pending technology, Quantum Fracturing, is based on the science of mass transfer and fluid fracturing. The company intends to license its technology to customers, such as fuel refiners, and chemical and oil companies. OriginOil, Inc. was founded in 2007 and is headquartered in Los Angeles, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net